naion glp-1 Risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients prescribed semaglutide - Novo Nordisk Newest Study of Semaglutide and
Description
doi: 10.1016/j.diabet.2025.101664
The FDA Reclassification Explained RFK announced 14 banned peptides returning to legal compounding but the FDA's July 23-24 vote only covers 7
doi: 10.1017/neu.2020.14
Once you reach your goal, you can: Taper off the medication Move to a lower maintenance dose Stay on temporarily with continued support We help clients transition off GLP-1s while keeping their progress
Knowing what to expect can help you choose the option that best fits your lifestyle and comfort level
